
1. int j parasitol drugs drug resist. 2015 nov 28;6(1):1-11. doi:
10.1016/j.ijpddr.2015.11.003. ecollection 2016 apr.

targeting plasmodium vivax equilibrative nucleoside transporter 1 (pvent1)
for antimalarial drug development.

deniskin r(1), frame ij(1), sosa y(1), akabas mh(2).

author information: 
(1)department physiology & biophysics, albert einstein college medicine,
bronx, new york, usa.
(2)department physiology & biophysics, albert einstein college medicine,
bronx, new york, usa; department neuroscience, albert einstein college of
medicine, bronx, new york, usa; department medicine, albert einstein college
of medicine, bronx, new york, usa. electronic address:
myles.akabas@einstein.yu.edu.

infection plasmodium falciparum vivax cause cases malaria.
emerging resistance current antimalarial medications makes new drug
development imperative. ideally new antimalarial drug treat both
falciparum vivax malaria. malaria parasites purine auxotrophic,
they rely purines imported host erythrocyte via equilibrative
nucleoside transporters (ents). thus, purine import transporters represent 
potential target antimalarial drug development. falciparum parasites 
primary purine transporter p. falciparum equilibrative nucleoside
transporter type 1 (pfent1). recently identified potent pfent1 inhibitors with
nanomolar ic50 values using robust, yeast-based high throughput screening
assay. current work characterized plasmodium vivax ent1 (pvent1)
homologue sensitivity pfent1 inhibitors. expressed yeast
codon-optimized pvent1 gene saccharomyces cerevisiae. pvent1-expressing yeast 
imported purines ([(3)h]adenosine) pyrimidines ([(3)h]uridine), whereas 
wild type (fui1δ) yeast not. based radiolabel substrate uptake inhibition 
experiments, inosine lowest ic50 (3.8 μm), compared guanosine (14.9
μm) adenosine (142 μm). pyrimidines, thymidine ic50 183 μm (vs.
cytidine uridine; mm range). ic50 values higher nucleobases compared
to corresponding nucleosides; hypoxanthine 25-fold higher ic50 than
inosine. archetypal human ent1 inhibitor 4-nitrobenzylthioinosine (nbmpr) had
no effect pvent1, whereas dipyridamole inhibited pvent1, albeit 40 μm
ic50, 1000-fold less sensitive human ent1 (hent1). pfent1 inhibitors
blocked transport activity pvent1 five known naturally occurring
non-synonymous single nucleotide polymorphisms (snps) similar ic50 values.
thus, pfent1 inhibitors also target pvent1. implies development 
novel antimalarial drugs target falciparum vivax ent1 may be
feasible.

doi: 10.1016/j.ijpddr.2015.11.003 
pmcid: pmc4706624
pmid: 26862473  [indexed medline]

